Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01551550 · ClinicalTrials.gov registry record · NA

Shunt Tube Exposure Prevention Study

A NA study, sponsored by BioTissue Holdings.

Completed
Registry status
NA
Development phase
82
Enrollment target

NCT01551550 is a NA study that has completed, run by BioTissue Holdings. The registered enrollment target is 82 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01551550, a NA study, has completed, sponsored by BioTissue Holdings.

COMPLETED
Registry status
NA
Development phase
82 participants
Enrollment target

Study Summary

This is a multi-site randomized clinical trial to evaluate the long-term efficacy of the thicker amniotic membrane graft (AmnioGuard™, Bio-Tissue, Inc, Miami, FL) in reducing shunt tube exposure in patients undergoing glaucoma drainage device implantation.

Interventions

  • PROCEDURE GDD
  • PROCEDURE Amniotic Membrane Graft
  • PROCEDURE Pericardial Graft

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2013-06
Est. Completion 2019-08-03
Phase NA

Sponsor

BioTissue Holdings

13 total trials

What the Registry Record Tells You About NCT01551550

The ClinicalTrials.gov registry entry for NCT01551550 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioTissue Holdings, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which GDD is the first listed.

NCT01551550 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01551550 about?

NCT01551550 is a clinical study titled "Shunt Tube Exposure Prevention Study". This is a multi-site randomized clinical trial to evaluate the long-term efficacy of the thicker amniotic membrane graft (AmnioGuard™, Bio-Tissue, Inc, Miami, FL) in reducing shunt tube exposure in patients undergoing glaucoma drainage device implantation.

What is the current status of trial NCT01551550?

This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 2013-06. Estimated completion is 2019-08-03.

What interventions are being tested in trial NCT01551550?

The interventions under investigation include: GDD (PROCEDURE), Amniotic Membrane Graft (PROCEDURE), Pericardial Graft (PROCEDURE).

Who is sponsoring clinical trial NCT01551550?

This trial is sponsored by BioTissue Holdings, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.